Skip to content
Ceftizoxime
Cefizox (ceftizoxime) is a small molecule pharmaceutical. Ceftizoxime was first approved as Cefizox on 1983-09-15. It is used to treat acinetobacter infections, bacterial infections, bacterial meningitis, bacterial pneumonia, and bacterial skin diseases amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
respiratory tract diseasesD012140
nervous system diseasesD009422
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ceftizoxime sodium
Tradename
Company
Number
Date
Products
CEFIZOXAstellas PharmaN-050560 DISCN1983-09-15
4 products
CEFIZOX IN PLASTIC CONTAINERAstellas PharmaN-050589 DISCN1995-04-13
2 products
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINERAstellas PharmaN-050589 DISCN1984-10-03
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acinetobacter infectionsEFO_1000792D000151—
bacterial infections—D001424A49
bacterial meningitisEFO_1000831D016920G00
bacterial pneumoniaEFO_1001272D018410J15.9
bacterial skin diseases—D017192—
bacteroides infectionsEFO_1000832D001442—
escherichia coli infectionsEFO_1001318D004927B96.20
gonorrheaDOID_7551D006069A54
haemophilus infectionsEFO_1001127D006192—
infectious bone diseases—D001850—
Show 10 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DD: Third-generation cephalosporins
— J01DD07: Ceftizoxime
HCPCS
Code
Description
J0715
Injection, ceftizoxime sodium, per 500 mg
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PyelonephritisD011704EFO_1001141N10-N16——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
PharmacokineticsD0105992————2
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular edemaD008269————11
Retinitis pigmentosaD012174HP_0000580H35.52————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEFTIZOXIME
INNceftizoxime
Description
Ceftizoxime is a parenteral third-generation cephalosporin, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position. It has a role as an antibacterial drug. It is a conjugate acid of a ceftizoxime(1-).
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1
Identifiers
PDB—
CAS-ID68401-81-0
RxCUI2192
ChEMBL IDCHEMBL528
ChEBI ID553473
PubChem CID6533629
DrugBankDB01332
UNII IDC43C467DPE (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,636 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
307 adverse events reported
View more details